Pituitary Cancer Market Research Report - Forecast till 2027

Pituitary Cancer Market Research Report: By Cancer Type (Adrenocorticotropic Hormone-Secreting [ACTH] Tumor, Growth Hormone-Secreting Tumor, Prolactin-Secreting Tumor and Thyroid-Stimulating Hormone-Secreting Tumor), Treatment Type (Chemotherapy, Surgery, Radiation Therapy and others), End User (Hospitals & Clinics, Research & Academic Institutes and others) and Region (Americas, Europe, Asia-Pacific and Middle East Africa) - Forecast till 2027

ID: MRFR/Pharma/1126-HCR | February, 2021 | Region : Global

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis


6. GLOBAL PITUITARY CANCER MARKET, BY CANCER TYPE

6.1. Overview

6.2. Adrenocorticotropic Hormone-Secreting (ACTH) Tumor

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Growth Hormone-Secreting Tumor

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Prolactin-Secreting Tumor

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5. Thyroid-Stimulating Hormone-Secreting Tumor

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL PITUITARY CANCER MARKET, BY TREATMENT TYPE

7.1. Overview

7.2. Surgery

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.1. Endoscopic Transnasal Transsphenoidal

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.2. Craniotomy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Radiation Therapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.1. Stereotactic Radiosurgery

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.2. External Beam Radiation

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.3. Intensity Modulated Radiation Therapy (IMRT)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.4. Proton Beam Therapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Chemotherapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL PITUITARY CANCER MARKET, BY END USER

8.1. Overview

8.2. Hospitals & Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Specialty Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9. GLOBAL PITUITARY CANCER MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

10. COMPANY LANDSCAPE

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Global Pituitary Cancer Market

10.5. Competitive Benchmarking

10.6. Leading Players in Terms of Number of Developments in the Global Pituitary Cancer Market

10.7. Key Developments and Growth Strategies

10.7.1. Product Launch/Service Deployment

10.7.2. Mergers and Acquisitions

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix & Market Ratio

10.8.1. Sales & Operating Income 2020

10.8.2. Major Players R&D Expenditure 2020

10.9. Major Players Capital Market Ratio

11. COMPANY PROFILES

11.1. Amgen Inc.

11.1.1. Company Overview

11.1.2. Product Overview

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Bristol-Myers Squibb Company

11.2.1. Company Overview

11.2.2. Product Overview

11.2.3. Financial Overview

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Celgene Corporation

11.3.1. Company Overview

11.3.2. Product Overview

11.3.3. Financial Overview

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. Eli Lilly and Company

11.4.1. Company Overview

11.4.2. Product Overview

11.4.3. Financial Overview

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. Astellas Pharma Inc.

11.5.1. Company Overview

11.5.2. Product Overview

11.5.3. Financial Overview

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. Merck & Co., Inc.

11.6.1. Company Overview

11.6.2. Product Overview

11.6.3. Financial Overview

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Novartis AG

11.7.1. Company Overview

11.7.2. Product Overview

11.7.3. Financial Overview

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. Pfizer Inc.

11.8.1. Company Overview

11.8.2. Product Overview

11.8.3. Financial Overview

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. AstraZeneca

11.9.1. Company Overview

11.9.2. Product Overview

11.9.3. Financial Overview

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Mylan NV

11.10.1. Company Overview

11.10.2. Product Overview

11.10.3. Financial Overview

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. Johnson & Johnson Services, Inc.

11.11.1. Company Overview

11.11.2. Product Overview

11.11.3. Financial Overview

11.11.4. Key Developments

11.11.5. SWOT Analysis

11.11.6. Key Strategies

11.12. Onxeo

11.12.1. Company Overview

11.12.2. Product Overview

11.12.3. Financial Overview

11.12.4. Key Developments

11.12.5. SWOT Analysis

11.12.6. Key Strategies

11.13. Ipsen Pharmaceuticals

11.13.1. Company Overview

11.13.2. Product Overview

11.13.3. Financial Overview

11.13.4. Key Developments

11.13.5. SWOT Analysis

11.13.6. Key Strategies

11.14. Salix Pharmaceuticals, Inc.

11.14.1. Company Overview

11.14.2. Product Overview

11.14.3. Financial Overview

11.14.4. Key Developments

11.14.5. SWOT Analysis

11.14.6. Key Strategies

11.15. Strides Pharma Science Limited

11.15.1. Company Overview

11.15.2. Product Overview

11.15.3. Financial Overview

11.15.4. Key Developments

11.15.5. SWOT Analysis

11.15.6. Key Strategies

11.16. Others

12. APPENDIX

12.1. References

12.2. Related Reports


LIST OF TABLES

TABLE 1 GLOBAL PITUITARY CANCER MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL PITUITARY CANCER MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL PITUITARY CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL PITUITARY CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL PITUITARY CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL PITUITARY CANCER MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: PITUITARY CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

TABLE 8 NORTH AMERICA: PITUITARY CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 9 NORTH AMERICA: PITUITARY CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 10 US: PITUITARY CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

TABLE 11 US: PITUITARY CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 12 US: PITUITARY CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 13 CANADA: PITUITARY CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

TABLE 14 CANADA: PITUITARY CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 15 CANADA: PITUITARY CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 16 LATIN AMERICA: PITUITARY CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

TABLE 17 LATIN AMERICA: PITUITARY CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 18 LATIN AMERICA: PITUITARY CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 19 EUROPE: PITUITARY CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

TABLE 20 EUROPE: PITUITARY CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 21 EUROPE: PITUITARY CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 22 WESTERN EUROPE: PITUITARY CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

TABLE 23 WESTERN EUROPE: PITUITARY CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 24 WESTERN EUROPE: PITUITARY CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 25 EASTERN EUROPE: PITUITARY CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

TABLE 26 EASTERN EUROPE: PITUITARY CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 27 EASTERN EUROPE: PITUITARY CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 28 ASIA-PACIFIC: PITUITARY CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

TABLE 29 ASIA-PACIFIC: PITUITARY CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 30 ASIA-PACIFIC: PITUITARY CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: PITUITARY CANCER MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: PITUITARY CANCER MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: PITUITARY CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)


LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE OF THE GLOBAL PITUITARY CANCER MARKET

FIGURE 3 MARKET DYNAMICS OF THE GLOBAL PITUITARY CANCER MARKET

FIGURE 4 GLOBAL PITUITARY CANCER MARKET SHARE, BY CANCER TYPE, 2020 (%)

FIGURE 5 GLOBAL PITUITARY CANCER MARKET SHARE, BY TREATMENT TYPE, 2020 (%)

FIGURE 6 GLOBAL PITUITARY CANCER MARKET SHARE, BY END USER, 2020 (%)

FIGURE 7 GLOBAL PITUITARY CANCER MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 AMERICAS: PITUITARY CANCER MARKET SHARE BY REGION, 2020 (%)

FIGURE 8 NORTH AMERICA: PITUITARY CANCER MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 9 EUROPE: PITUITARY CANCER MARKET SHARE, BY REGION, 2020 (%)

FIGURE 10 WESTERN EUROPE: PITUITARY CANCER MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 ASIA-PACIFIC: PITUITARY CANCER MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 MIDDLE EAST & AFRICA: PITUITARY CANCER MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 GLOBAL PITUITARY CANCER MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 14 AMGEN INC..: KEY FINANCIALS

FIGURE 15 AMGEN INC.: SEGMENTAL REVENUE

FIGURE 16 AMGEN INC.: REGIONAL REVENUE

FIGURE 17 BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS

FIGURE 18 BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE

FIGURE 19 BRISTOL-MYERS SQUIBB COMPANY: REGIONAL REVENUE

FIGURE 20 CELGENE CORPORATION: KEY FINANCIALS

FIGURE 21 CELGENE CORPORATION: SEGMENTAL REVENUE

FIGURE 22 CELGENE CORPORATION: REGIONAL REVENUE

FIGURE 23 ELI LILLY AND COMPANY: KEY FINANCIALS

FIGURE 24 ELI LILLY AND COMPANY: SEGMENTAL REVENUE

FIGURE 25 ELI LILLY AND COMPANY: REGIONAL REVENUE

FIGURE 26 ASTELLAS PHARMA INC.: KEY FINANCIALS

FIGURE 27 ASTELLAS PHARMA INC.: SEGMENTAL REVENUE

FIGURE 28 ASTELLAS PHARMA INC.: REGIONAL REVENUE

FIGURE 29 MERCK & CO., INC.: KEY FINANCIALS

FIGURE 30 MERCK & CO., INC.: SEGMENTAL REVENUE

FIGURE 31 MERCK & CO., INC.: REGIONAL REVENUE

FIGURE 32 NOVARTIS AG: KEY FINANCIALS

FIGURE 33 NOVARTIS AG: SEGMENTAL REVENUE

FIGURE 34 NOVARTIS AG: REGIONAL REVENUE

FIGURE 35 PFIZER INC.: KEY FINANCIALS

FIGURE 36 PFIZER INC.: SEGMENTAL REVENUE

FIGURE 37 PFIZER INC.: REGIONAL REVENUE

FIGURE 38 ASTRAZENECA: KEY FINANCIALS

FIGURE 39 ASTRAZENECA: SEGMENTAL REVENUE

FIGURE 40 ASTRAZENECA: REGIONAL REVENUE

FIGURE 41 MYLAN N.V.: KEY FINANCIALS

FIGURE 42 MYLAN N.V.: SEGMENTAL REVENUE

FIGURE 43 MYLAN N.V.: REGIONAL REVENUE

FIGURE 44 JOHNSON & JOHNSON SERVICES, INC.: KEY FINANCIALS

FIGURE 45 JOHNSON & JOHNSON SERVICES, INC.: SEGMENTAL REVENUE

FIGURE 46 JOHNSON & JOHNSON SERVICES, INC.: REGIONAL REVENUE

FIGURE 47 ONXEO: KEY FINANCIALS

FIGURE 48 ONXEO: SEGMENTAL REVENUE

FIGURE 49 ONXEO: REGIONAL REVENUE

FIGURE 50 IPSEN PHARMACEUTICALS: KEY FINANCIALS

FIGURE 51 IPSEN PHARMACEUTICALS: SEGMENTAL REVENUE

FIGURE 52 IPSEN PHARMACEUTICALS: REGIONAL REVENUE

FIGURE 53 SALIX PHARMACEUTICALS, INC.: KEY FINANCIALS

FIGURE 54 SALIX PHARMACEUTICALS, INC.: SEGMENTAL REVENUE

FIGURE 55 SALIX PHARMACEUTICALS, INC.: REGIONAL REVENUE

FIGURE 56 STRIDES PHARMA SCIENCE LIMITED: KEY FINANCIALS

FIGURE 57 STRIDES PHARMA SCIENCE LIMITED: SEGMENTAL REVENUE

FIGURE 58 STRIDES PHARMA SCIENCE LIMITED: REGIONAL REVENU

Pituitary Cancer Market